Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2J2 | P51589 | 2/20 | 0.46 |
| ▸ | RBP4 | P02753 | 4/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.43 |
| ▸ | KDM5A | P29375 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13873159 | 0.93 | GAA (0.42) | EPHX2CYP2C9CYP2J2RBP4CYP2C19 | |
| SCHEMBL13873112 | 0.92 | EPHX2 (0.56) | EPHX2CYP2C9CYP2J2RBP4CYP2C19 | |
| SCHEMBL13873201 | 0.81 | EPHX2 (0.50) | EPHX2CYP2C9CYP2J2 | |
| SCHEMBL6123596 | 0.81 | EPHX2 (0.48) | EPHX2CYP2C9CYP2J2CYP2C19HMOX1 | |
| SCHEMBL7900769 | 0.81 | PIK3CD (0.56) | GPR119PIK3CD | |
| SCHEMBL4102372 | 0.81 | PIK3CD (0.56) | GPR119PIK3CD | |
| SCHEMBL1739282 | 0.79 | EPHX2 (0.52) | EPHX2CYP2C9CYP2J2RBP4CYP2C19 | |
| SCHEMBL13873153 | 0.79 | SMN1; SMN2 (0.47) | EPHX2CYP2C9CYP2J2RBP4CYP2C19 | |
| SCHEMBL13873148 | 0.78 | EPHX2 (0.61) | EPHX2CYP2C9CYP2J2RBP4SMN1; SMN2 | |
| SCHEMBL25595697 | 0.76 | SMN1; SMN2 (0.59) | SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885CYP2C9 477/4885CYP2J2 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.